Skip to main content
. 2014 Nov 21;20(43):15992–16013. doi: 10.3748/wjg.v20.i43.15992

Figure 1.

Figure 1

Hepatitis C virus genome and nucleotide variability. A schematic representation of the viral genome is depicted. The degree of nucleotide variability along the viral genome is also shown. The target molecules for anti-HCV therapy are noted, and the antiviral agents are indicated. A selection of FDA approved and in development compounds are shown. Roman numerals in brackets indicate the current clinical phase of development. HCV: Hepatitis C virus; FDA: Food and Drug Administration; PI: Protease inhibitors.